文献速递生殖医学

促性腺激素与口服促排卵药治疗不明原因不孕的系统评价与荟萃分析

Gonadotropins versus oral ovarian stimulation agents for unexplained infertility: a systematic review and meta-analysis.
PubMed 文献 · Fertil Steril · 2020-01-20

该系统评价与荟萃分析纳入8项试验、2,989例不明原因不孕行宫腔内人工授精联合卵巢刺激的患者,比较口服药与促性腺激素的活产与多胎妊娠。促性腺激素组活产相对风险1.09,多胎妊娠相对风险1.06;宽松取消政策或高剂量方案临床妊娠更高但多胎风险亦升高。随机数据不支持促性腺激素用于此类患者。

要点

  • 促性腺激素每获得一次活产,多胎妊娠风险相似增加。
  • 促性腺激素组活产RR 1.09,多胎妊娠RR 1.06。
  • 宽松取消政策或多胎风险RR分别升至1.20与1.15。

核心结论

  • 随机数据不支持对不明原因不孕行宫腔内人工授精联合卵巢刺激时使用促性腺激素。
  • 促性腺激素每获得一次活产伴随相似的多胎妊娠风险增加。

研究设计与样本

  • 系统评价与荟萃分析,纳入8项符合标准的试验,共2,989例患者、6,590个周期。
  • 研究对象为不明原因不孕接受宫腔内人工授精联合卵巢刺激的患者,干预为克罗米芬、来曲唑或促性腺激素。

主要发现

  • 促性腺激素组活产的相对风险为1.09。
  • 促性腺激素组多胎妊娠的相对风险为1.06。
  • 宽松取消政策方案临床妊娠更高,后续多胎妊娠相对风险为1.20。
  • 较高促性腺激素剂量方案临床妊娠更高,后续多胎妊娠相对风险为1.15。
  • 两组每例患者的单胎出生数相似;符合方案、每周期或固定效应模型敏感性分析结果未变。

关键数值与推荐

  • 活产相对风险1.09(促性腺激素 vs 口服药)。
  • 多胎妊娠相对风险1.06(促性腺激素 vs 口服药)。
  • 宽松取消政策下多胎妊娠相对风险1.20。
  • 较高促性腺激素剂量下多胎妊娠相对风险1.15。

临床怎么用

  • 不明原因不孕行宫腔内人工授精联合卵巢刺激时,优先考虑口服促排卵药而非促性腺激素。
  • 若使用促性腺激素,需警惕多胎妊娠风险,宽松取消政策或高剂量方案风险更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare live birth and multiple gestation in patients diagnosed with unexplained infertility undergoing intrauterine insemination after ovarian stimulation (OS-IUI) with oral medications versus gonadotropins. DESIGN: Systemic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Patients undergoing OS-IUI for treatment of unexplained infertility. INTERVENTION(S): Clomiphene, letrozole, or gonadotropins for OS-IUI. MAIN OUTCOME MEASURE(S): Live birth and multiple gestation. RESULT(S): Eight total trials were identified that met the inclusion criteria and comprised 2,989 patients undergoing 6,590 cycles. One study reported a significant increase in both live births and multiple gestations with the use of gonadotropins, two studies found an increased likelihood of live birth with the use of gonadotropins, and two studies found an increased risk of twins with gonadotropins. The relative risk of live birth in subjects receiving gonadotropins was 1.09. The relative risk of multiple gestation in subjects receiving gonadotropins was 1.06. Clinical pregnancy was higher in protocols with lax cancellation policies or higher gonadotropin doses, with subsequent increased relative risks of multiple gestations of 1.20 and 1.15, respectively. Singleton births per subject were similar between the two groups. The results did not change in per-protocol, per cycle, or fixed-effect model sensitivity analyses. CONCLUSION(S): For every birth gained with the use of gonadotropins, a similar increased risk of multiple gestation occurs. The randomized data do not support the use of gonadotropin for OS-IUI in women with unexplained infertility. CLINICAL TRIAL REGISTRATION NUMBER: Prospero CRD4201911998.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Zolton JR, Lindner PG, Terry N, et al. Gonadotropins versus oral ovarian stimulation agents for unexplained infertility: a systematic review and meta-analysis. Fertil Steril. 2020. PMID: 31973903. doi:10.1016/j.fertnstert.2019.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。